Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for BMI Reduction in Type 2 Diabetes
NCT07367555Phase 1Completed
- Sponsor
- Ariba Shafiq
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ariba Shafiq. Primary endpoint: Body Weight at 3 months. Started Oct 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07367555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07367555.